A majority of leading commercial entities active in the CRISPR space originate in the United States, while patents filed by academic research institutions appears to slightly more evenly divided between organizations in China and United States. Among the various gene targets occurring in the CRISPR dataset, TP53 emerges as the clear leader, growing drastically after 2018. Perhaps unsurprising since mutations in TP53 have been linked to various types of cancer. These mutations tend to be missense mutations and present great opportunities for the use of CRISPR/Cas technology in correcting/rectifying them. Other notable gene targets appearing frequently include c-myc, HBB, c-Ki-Ras and BRCA1.